

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/013655 A2

(51) International Patent Classification⁷: **A61P 3/12**, 7/10, 21/00, 25/08, 27/02, 27/06, 35/00, 35/02, 43/00, A61K 31/635, 45/06, 31/18, 31/415, 31/42, 31/4188

(21) International Application Number: PCT/US02/25447

(22) International Filing Date: 9 August 2002 (09.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/311,561 10 August 2001 (10.08.2001) US

(71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Department, 800 N. Lindbergh Boulevard - 04E, St. Louis, MO 63167 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **O'NEAL, Janet, M.** [US/US]; 4046 Parker Avenue, St. Louis, MO 63116 (US). **MASFERRER, Jaime, L.** [CL/US]; 812 Courtwood Lane, Ballwin, MO 63011 (US).

(74) Agents: **POLSTER, Philip, B., II** et al.; Pharmacia Corporation, Corporate Patent Department, 800 North Lindbergh Blvd., Mail Zone 04E, St. Louis, MO 63167 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBONIC ANHYDRASE INHIBITOR

(57) Abstract: Methods of treating or preventing carbonic anhydrase associated disorders or diseases in a subject in need of such treatment as prevention comprising the administration of cyclooxygenase -2 inhibitors, or structurally related compounds, having carbonic anhydrase inhibitory properties, as well as combinations of the cyclooxygenase -2 inhibitors, or structurally related compounds, with anti-inflammatory agents or drugs, antineoplastic agents or drugs or ophthalmic agents or drugs in methods of treatment and prevention of disorders or diseases.



WO 03/013655 A2

CARBONIC ANHYDRASE INHIBITOR

FIELD OF INVENTION

5 This application claims priority to provisional application Serial No. 60/311,561 filed August 10, 2001.

 The present invention relates in general to the use of carbonic anhydrase inhibitors, drugs, or agents in medicine and, more specifically, to the use of compounds that exhibit carbonic anhydrase (CA) inhibitor activity and compounds
10 that exhibit both carbonic anhydrase (CA) and cyclooxygenase-2 (COX-2) inhibitor activity, in methods of treatment of diseases associated with the isozymes of carbonic anhydrase or with COX-2, or both.

BACKGROUND OF THE INVENTION

 Carbonic anhydrases are metalloprotein enzymes which catalyze the hydration
15 of carbon dioxide and the dehydration of bicarbonate: $\text{CO}_2 + \text{H}_2\text{O} \rightarrow \text{HCO}_3^- + \text{H}^+$. The carbonic anhydrases are widespread in nature and found in animals, plants and certain bacteria. In humans CA has at least fourteen (14) isoenzymes with different physiological functions. (Scozzafava et al, *J.Med.Chem.*, 43:3677-3687, 2000). The CA isozymes are involved in respiration and transport of CO_2 /bicarbonate between
20 metabolizing tissues and the lungs, pH homeostasis, electrolyte secretion in a variety of tissues, and biosynthetic reactions such as lipogenesis, gluconeogenesis, and ureagenesis.

 Carbonic anhydrase inhibitors initially were developed as diuretics for the treatment of edema. One mechanism of the diuretic action is due to the inhibitory
25 effect of sulfanilamide on the carbonic anhydrase enzyme, resulting in increased bicarbonate excretion and obligatory water loss through the kidneys. Although


carbonic anhydrase inhibitors may be used to treat edema associated with congestive heart failure and for drug-induced edema, presently the major indication for carbonic anhydrase inhibitors is for treatment of open-angle glaucoma. Also the carbonic anhydrase inhibitors may be used to treat secondary glaucoma and preoperatively in acute angle closure glaucoma before surgery.

Carbonic anhydrase inhibitors also are used to treat optic neuropathy associated with elevated intracranial pressure and to treat pseudomotor cerebri in headache management. Carbonic anhydrase inhibitors have been used to treat cystoid macular edema (CME). (Wolfensberger, T.J., *Doc Ophthalmol* 1999; 97 (3-4):387-97).

Acetazolamide has been shown to potentiate the antitumor activity of 1-phthalidyl 5-fluorouracil (PH-5-FU). (Hisanori Kaisai. et. al, *Cancer Chemother Pharmacol.* 1986; 16(1):55-7). Acetazolamide was shown to reduce invasiveness of certain renal cancer cell lines. (Parkkila, S. et al, *PNAS*, 97:5:2220-2224, 2000). Some thiadiazole-2-sulfonamide carbonic anhydrase inhibitors have been shown to inhibit cell growth in leukemia, non-small cell lung cancer, ovarian cancer, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. (C. Supuran, et al, *Eur.J.Med.Chem*, 35: 867-874 (2000)).

SUMMARY OF THE INVENTION

One exemplary embodiment of the invention provides a method of treating or preventing a carbonic anhydrase-associated disorder in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing- effective amount of a compound of formula 1:



1.

wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

5 wherein R¹ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxy carbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

10 wherein R² is selected from the group consisting of amino and aminoalkylcarbonyl; and

wherein R³ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, alkylthiocarbonyl, hydroxyalkyl, alkoxy carbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxy carbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-aryl amino, N-aralkyl amino, N-alkyl-N-aralkyl amino, N-alkyl-N-aryl amino, aminoalkyl, alkylaminoalkyl, N-aryl aminoalkyl, N-aralkyl aminoalkyl, N-alkyl-N-aralkyl aminoalkyl, N-alkyl-N-aryl aminoalkyl, aryloxy,


15

20

aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylamino sulfonyl, arylsulfonyl, N-alkyl-N-arylamino sulfonyl; and heterocyclyalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl, or a pharmaceutically acceptable salt or prodrug thereof, to treat or prevent the disorder.

- 5 Another exemplary embodiment of the invention provides a method of treating or preventing carbonic anhydrase-associated disorders in a subject in need of such treatment or prevention, comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing-effective amount of a compound of formula 1:

10



1.

- wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;
- 15 wherein R¹ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxy carbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
- 20 wherein R² is selected from the group consisting of amino and aminoalkylcarbonyl; and

wherein R³ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocycl, cycloalkenyl, aralkyl, heterocyclalkyl, acyl, alkylthioalkyl, alkylthiocarbonyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminalkyl, N-aralkylaminalkyl, N-alkyl-N-aralkylaminalkyl, N-alkyl-N-arylaminalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; and heterocyclyalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl, or a pharmaceutically acceptable salt or prodrug thereof, to treat or prevent the disorder.

One exemplary embodiment of the invention provides a method of treating or preventing a carbonic anhydrase associated disorder in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing-effective amount of a cyclooxygenase-2 inhibitor compound having a sulfonamide structure thereon, a pharmaceutically acceptable salt thereof or prodrug to treat or prevent the disorder.


Another exemplary embodiment of the invention provides a method of treatment of a neoplastic disorder or disease in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor

treating- or preventing- effective amount of a cyclooxygenase -2 inhibitor a pharmaceutically acceptable salt thereof or prodrug to treat or prevent the disorder.

Another exemplary embodiment of the invention provides a method of treatment of a neoplastic disorder or disease in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing- effective amount of a cyclooxygenase -2 inhibitor a pharmaceutically acceptable salt or prodrug thereof to treat or prevent the disorder, wherein the neoplastic disorder includes, but is not limited to: renal cancer; leukemia; lung cancer; ovarian cancer; melanoma; colon cancer; cancer of the central nervous system; prostate cancer and breast cancer.

Another exemplary embodiment of the invention provides a method of treating or preventing carbonic anhydrase -associated disorders in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing- effective amount of a cyclooxygenase -2 inhibitor a pharmaceutically acceptable or prodrug thereof to treat or prevent the disorder, wherein the carbonic anhydrase-associated disorder includes, but is not limited to: edema; open-angle glaucoma; secondary glaucoma; acute angle closure glaucoma; epilepsy; acute mountain sickness; familial periodic paralysis; metabolic alkylosis; optic neuropathy; pseudomotor cerebri and cystoid macular edema.

An exemplary embodiment of the invention provides a method of treatment of a neoplastic disorder or disease in a subject in need of such treatment or prevention comprising the administration to the subject an antineoplastic drug or agent and a carbonic anhydrase inhibitor treating- or preventing- effective amount of a compound of formula 1:



1.

wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

5 wherein R¹ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

10 wherein R² is selected from the group consisting of amino and aminoalkylcarbonyl; and

wherein R³ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, alkylthiocarbonyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylaminocarbonyl, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylaminocarbonyl, aminoalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-aralkylaminocarbonyl, N-alkyl-N-aralkylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, aryloxy,


15

20


aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylamino sulfonyl, arylsulfonyl, N-alkyl-N-arylamino sulfonyl; and heterocyclyalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl, or a pharmaceutically acceptable salt thereof, to prevent or treat the neoplastic disorder.

- 5 One exemplary embodiment of the invention provides a method of treating or preventing a carbonic anhydrase associated disorder in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing- effective amount of a compound selected from the group of compounds of the formulas:


10




I.;




II.;




III.;




IV.;



V.;




VI.; and




VII.

or a pharmaceutically acceptable salt or prodrug thereof.


One exemplary embodiment of the invention provides a method of treating or
 5 preventing a carbonic anhydrase associated disorder in a subject in need of such
 treatment or prevention comprising the administration to the subject a carbonic
 anhydrase inhibitor treating- or preventing- effective amount of a compound selected
 from the group consisting of the formulas:




I.;



V.;








VII.; and




or a pharmaceutically acceptable salt or prodrug thereof.


Another embodiment of the invention includes a method of preventing or
 5 treating an ophthalmic disorder or disease in a subject in need of such prevention or
 treatment, comprising the administration of an ophthalmic disorder or disease
 preventing or treating amount of a carbonic anhydrase inhibitor selected from the
 group of compounds consisting of the compound of formulas:

10






VI.; and




VII.

or a pharmaceutically acceptable salt or prodrug thereof, together with at least one
5 different ophthalmic agent.


The invention also includes a method for treating or preventing a neoplasia
disorder in a mammal in need of such treatment or prevention, which method
comprises treating the mammal with a therapeutically effective amount of a
combination comprising an antineoplastic drug or agent and a carbonic anhydrase
10 inhibitor selected from the group of carbonic anhydrase inhibitors consisting of the
formulas:




I.;




II.;




III.;




IV.;



V.;




VI.;




VII.;


5



XI.;



XII.; and



XIII.

or a pharmaceutically acceptable salt or prodrug thereof.

DETAILED DESCRIPTION OF THE INVENTION

Generally, the present invention encompasses agents that inhibit isozymes of carbonic anhydrase and their method of use in medicine in preventing or treating various diseases or conditions in which carbonic anhydrase is implicated or involved in metabolic pathways that influence the diseases or conditions. The term "carbonic anhydrases" as used herein refers to the metalloprotein enzymes which catalyze the simple interconversion of CO_2 and H_2CO_3 ($\text{CO}_2 + \text{H}_2\text{O} \rightarrow \text{HCO}_3^- + \text{H}^+$).


The term "carbonic anhydrase inhibitor" as used herein refers to agents that reduce or inhibit the activity of human carbonic anhydrases.

The term "CA" as used herein is an abbreviation of carbonic anhydrase.

The term "CA II" as used herein means the 260 amino acid protein human carbonic anhydrase II enzyme.

The term "TRIS buffer" as used herein means Tris hydroxymethylaminoethane, $\text{NH}_2\text{C}(\text{CH}_2\text{OH})_3$, CAS number 00077-86-1.


Aminoalkylcarbonyl as used herein means a straight or branched chain carbon substituent having a nitrogen atom adjacent to a carbonyl carbon, wherein the carbonyl carbon is double-bonded to an oxygen atom, and wherein the point of attachment is at an open valence of the nitrogen atom. An exemplary aminoalkylcarbonyl is:



, wherein the undulate line denotes the point of attachment.

Heterocyclalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl as used herein means a straight or branched chain glycol substituent having a terminal heterocycle moiety, an aminocarbonyl moiety, and an alkylcarbonylthionyl moiety at the point of attachment.

An exemplary heterocyclalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl has the formula:



wherein the undulate line denotes the point of attachment.

The invention also encompasses some agents that exhibit more than one therapeutic effect, in that they inhibit carbonic anhydrases and inhibit cyclooxygenase-2 (COX-2), concomitantly. Some of the agents have utility in the treatment of carbonic anhydrase and COX-2 associated disorders, diseases or physiological conditions. The agents have therapeutic applications such as treatment of ophthalmic or ocular diseases, such as glaucoma and macular degeneration, inflammatory conditions and neoplastic diseases or conditions. The invention also encompasses therapeutic combinations of the carbonic anhydrase inhibitors with other therapeutic agents, such as ophthalmic drugs or agents and antineoplastic agents.


As set out in detail immediately below, Compounds I, II, III, IV, V, VI and VII demonstrate carbonic anhydrase inhibition *in vitro*. In summary, Compound I is a potent inhibitor of carbonic anhydrase, with an IC_{50} of 20nM. Compound I is a more potent inhibitor than acetazolamide (IC_{50} of 30nM). The selective COX-2

inhibitors having sulfonamide structures, celecoxib (Compound V) and valdecoxib (Compound VII), inhibit carbonic anhydrase with an average IC_{50} of 140nM and 330nM, respectively. The selective COX-2 inhibitor rofecoxib (Compound VIII) did not exhibit significant carbonic anhydrase inhibition.


EXAMPLE

The inhibitory activity of COX-2 inhibitors and other structurally related compounds on human carbonic anhydrase activity was investigated.


Compounds Tested :




VI.




VII.




VIII.



IX.




X.



Description Of The Compounds:

Acetazolamide (5-Acetamido-1,3,4-thiadiazole-2-sulfonamide) is a known carbonic anhydrase inhibitor, and was included in the example as a standard.

Compounds I, II, III, IV, V, VI, VII, XI and XII are structurally related compounds represented by the general structure of Formula 1.:



1.

wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

wherein R¹ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R² is selected from the group consisting of amino and aminoalkylcarbonyl; and

wherein R³ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, alkylthiocarbonyl,

hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminalkyl, N-aralkylaminalkyl, N-alkyl-N-aralkylaminalkyl, N-alkyl-N-arylaminalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; and heterocyclyalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl, or a pharmaceutically acceptable salt thereof.

Compound V (celecoxib) is a selective cyclooxygenase-2 inhibitor, described in detail in U.S. Patent No. 5,466,823, which is incorporated herein by reference. Compound VII (valdecoxib) also is a selective cyclooxygenase-2 inhibitor, disclosed in detail in U.S. Patent No. 5,633,272, incorporated herein by reference. Compound VIII (rofecoxib) is a selective cyclooxygenase-2 inhibitor, described in detail in U.S. Patent No. 5,691,375, which is incorporated herein by reference. Compound IV exhibits cyclooxygenase inhibitor activity, but appears to be more selective for COX-2 than COX-1. Compound I and Compound VI do not inhibit cyclooxygenase-1 (COX-1) but weakly inhibit COX-2. Compounds II, III, IX, and X do not exhibit cyclooxygenase inhibitory activity.

The terms "cyclooxygenase-1" and "COX-1" used interchangeably herein refer to the constitutive isoform of the enzyme cyclooxygenase. The terms "cyclooxygenase-2" and "COX-2" as used interchangeably herein refer to the inducible isoform of the enzyme cyclooxygenase. The term "COX-2 selectivity" has been given

numerous and varied definitions in the published literature. Selectivity has been understood to refer, alternatively, to a variety of in vitro conditions and to a variety of in vivo conditions. In vitro selectivity does not necessarily mean the same thing as in vivo selectivity. However, as used herein, the terms "cyclooxygenase-2 selective inhibitor" and "COX-2 selective inhibitor" are used interchangeably herein and for the present invention refer to a therapeutic compound that inhibits cyclooxygenase-2 more than it inhibits cyclooxygenase-1 in an in vitro recombinant enzyme assay. The term "cyclooxygenase-2 inhibitor" or "COX-2 inhibitor" refers to any compound which inhibits the COX-2 enzyme, without regard to the extent to which it inhibits COX-1. Especially suitable as cyclooxygenase-2 selective inhibitors useful in the present invention are those compounds that have a cyclooxygenase-2 IC₅₀ of less than about 0.2 μ M, and also have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the cyclooxygenase-2 selective inhibitor compounds have a cyclooxygenase-1 IC₅₀ of greater than about 1 μ M, and more preferably of greater than 10 μ M.

Materials and Methods:

100 μ L	0.04 M Tris Buffer pH 7.6
10 μ L	Carbonic Anhydrase II Enzyme 500 Units/mL (Sigma C-6165)
20 μ L	Inhibitor Compound
70 μ L	3mM p-nitrophenyl acetate substrate (Sigma N-8130)

Each Inhibitor Compound was incubated at room temperature with 100 μ L 0.04M Tris Buffer (pH 7.6), 10 μ L Carbonic Anhydrase II Enzyme (500 Units/mL)

and 70 μ L 3mM p-nitrophenyl acetate substrate in a 96 well plate, and absorbance was read at 405 nm.

Table 1, below, lists the assay results for the compounds:

Table 1.

COMPOUND	CA Assay N IC ₅₀ (μ M)	SULFONAMIDE STRUCTURE ?
I	3 0.01 (0.015, 0.021, .004)	YES
Acetazolamide	4 0.03 (0.04, 0.017, 0.03, .017)	YES
II.	2 0.04 (0.03, 0.04)	YES
III.	1 0.04	YES
IV	1 0.09	YES
V.	3 0.14 (0.16, 0.15, .10)	YES
Celecoxib		
VI.	1 0.18	YES
VII.	2 0.33 (0.4, 0.25)	YES
Valdecoxib		
VIII.	1 >100	NO
Rofecoxib/Vioxx		
IX.	1 >100	NO
X.	1 >100	NO

Results:



All compounds tested containing a sulfonamide structure inhibited CA II. The selective COX-2 inhibitors, celecoxib and valdecoxib, inhibited CA II activity with IC₅₀s of 0.14 μ M and 0.33 μ M, respectively. The selective COX-2 inhibitor rofecoxib did not inhibit the enzyme up to 100 μ M. The known inhibitor of carbonic anhydrase, acetazolamide, and Compound I, blocked CA II activity with IC₅₀s of 0.03 μ M and 0.01 μ M, respectively.

Methods of Treatment:


The compounds shown to inhibit carbonic anhydrase can be used in methods of treatment or prevention of any carbonic anhydrase associated disorder, disease or physiological condition in a subject in which the inhibition of carbonic anhydrase enzymes effects treatment or prevention of the disorder, disease or physiological condition. The Compounds I, II, III, IV, V, VI, VII, XI, XII or XIII, or pharmaceutical salts thereof or prodrugs may be used for any medical indication in which carbonic anhydrase inhibitors have been shown to be effective or may be effective, alone or in combination. Furthermore, other related compounds having a sulfonamide group, and which exhibit carbonic anhydrase inhibition, are within the scope of the invention. For example, the following is an exemplary list of structurally related compounds known to be selective COX-2 inhibitors that include a sulfonamide group: Compound XI (deracoxib) and Compound XII (JTE-522) or a pharmaceutically acceptable salts or prodrug thereof.

Table 2.

Examples of Other Tricyclic COX-2 Selective
Having A Sulfonamide Group

<u>Compound Number</u>	<u>Structural Formula</u>
XI	
XII	

Compound XIII (parecoxib), below, which is a therapeutically effective prodrug of the tricyclic cyclooxygenase-2 selective inhibitor Compound VII (valdecoxib) (U.S. 5,932,598, herein incorporated by reference), may be advantageously employed as a source of a cyclooxygenase inhibitor having carbonic anhydrase inhibitor activity



XIII.

Suitable routes of administration of the compounds of the present invention include any means that produce contact of these compounds with their site of action in

the subject's body. More specifically, suitable routes of administration include oral, intravenous, subcutaneous, rectal, topical, buccal (i.e. sublingual), intramuscular, and intradermal. In an exemplary embodiment, the combinations are orally administered.

Pharmaceutically acceptable salts are particularly suitable for medical applications because of their greater solubility relative to the parent compound. Such salts must clearly have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention include when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfonic, sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothiocyanic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. The chloride salt is especially suitable for medical purposes. Suitable pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, and alkaline earth salts such as magnesium and calcium salts.

The compounds useful in the present invention are presented with an acceptable carrier in the form of a pharmaceutical combination. The carrier must be acceptable in the sense of being compatible with the other ingredients of the pharmaceutical combination and must not be deleterious to the subject. Suitable forms for the carrier include solid or liquid or both, and in an exemplary embodiment the carrier is formulated with the therapeutic compound as a unit-dose combination, for example as a tablet that contains from about 0.05% to about 95% by weight of the active compound. In alternative embodiments, other pharmacologically active substances are also present, including other compounds of the present invention. The

pharmaceutical combinations of the present invention are prepared by any of the well-known techniques of pharmacy, consisting essentially of admixing the ingredients.

Preferred unit dosage formulations are those containing an effective dose, as herein below described, or an appropriate fraction thereof, of one or more of the therapeutic compounds of the combinations.

In general, a total daily dose of a cyclooxygenase-2 inhibitor in the combinations is in the range of about 0.3 to about 100 mg/kg body weight/day, preferably from about 1 mg to about 50 mg/kg body weight/day, and more preferably from about 3 mg to about 10 mg/kg body weight/day.

In the case of pharmaceutically acceptable salts of the therapeutic compounds, the weights indicated above refer to the weight of the acid equivalent or the base equivalent of the therapeutic compound derived from the salt.

It should be understood that the amount of each compound that is required to achieve the desired biological effect depends on a number of factors such as the specific individual compounds chosen, the specific use for which it is intended, the route of administration, the clinical condition of the subject, and the age, weight, gender, and diet of the subject.

The daily doses described in the preceding paragraphs for the various therapeutic compounds are administered in a single dose, or in proportionate multiple subdoses. Subdoses are administered from two to six times per day. In one embodiment, doses are administered in sustained release form effective to obtain the desired biological effect.

Oral delivery of the compounds of the present invention can include formulations, as are well known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms. These include,

but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form.

Oral delivery of the compounds of the present invention can be achieved using a solid, semi-solid or liquid dosage form. Suitable semi-solid and liquid forms include, for example, a syrup or liquid contained in a gel capsule.

Pharmaceutical compositions suitable for oral administration can be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of at least one of the therapeutic compounds useful in the combinations of the present invention; as a powder or in granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.

One embodiment of the present invention is the treatment and prevention of carbonic anhydrases associated disorders or diseases in a subject in wherein administration of carbon anhydrase inhibitor to the subject is known to be effective in the treatment or prevention of the disorder or disease. These disorders and diseases include, but are not limited to, edema associated with congestive heart failure and for drug-induced edema; open-angle glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma before surgery, epilepsy, the prophylaxis and symptomatic treatment of acute mountain sickness, familial periodic paralysis, metabolic alkalosis, particularly alkalosis caused by diuretic induced increases in H^+ excretion, optic neuropathy associated with elevated intracranial pressure,

pseudomotor cerebri in headache management, cystoid macular edema; cystoid macular edema due to retinitis pigmentosa.

Another embodiment of the invention is the treatment and prevention of neoplastic disorders or diseases in a subject wherein administration of carbon anhydrase inhibitor to the subject is effective in the treatment or prevention of the neoplastic disorder or disease. Such neoplastic disorders or diseases include, but not limited to, renal cancer, leukemia, non-small cell lung cancer, ovarian cancer, melanoma, colon cancer, CNS cancers, prostate and breast cancer.

One embodiment of the invention includes methods of treatment or prevention of carbonic anhydrases associated disorders or diseases in a subject in need of such treatment or prevention, wherein administration Compound I, II, III, IV, V, VI, or VII, or a pharmaceutically acceptable salt or prodrug thereof, to the subject is effective in the treatment or prevention of the disorder or disease.

Compound V (celecoxib) and Compound VII (valdecoxib), which are shown to inhibit carbonic anhydrase, are selective COX-2 inhibitors. Compound V and Compound VII, as well as other COX-2 inhibitors structurally related to Compound V and VII that have sulfonamide structures thereon, pharmaceutical salts or prodrugs thereof, may be used for any indications in which CA inhibitor and a COX-2 inhibitor would be indicated. Such indications include, but are not limited to, treating ophthalmic or ocular inflammation and more preferably in method of treatment of ophthalmic diseases such as retinitis, conjunctivitis, retinopathies, uveitis and ophthalmic or ocular photophobia, and of acute injury to eye tissue where there is increased intraocular pressure that responds to treatment with carbonic anhydrase inhibitor drugs or agents. Further, those compounds that are both COX-2 inhibitors and carbonic anhydrase inhibitors are useful for treatment of corneal graft rejection,

ophthalmic or ocular neovascularization, retinal neovascularization including that following injury or infection, diabetic retinopathy, macular degeneration, retrolental fibroplasia and neovascular glaucoma. International Patent Publication No. WO 00/32189, which is incorporated herein by reference, describes orally deliverable compositions of celecoxib having utility in treatment of ophthalmic diseases such as retinitis, conjunctivitis, retinopathies, uveitis and ophthalmic or ocular photophobia, and of acute injury to eye tissue. It is describes that the subject orally deliverable compositions are useful for treatment of corneal graft rejection, ophthalmic or ocular neovascularization, retinal neovascularization including that following injury or infection, diabetic retinopathy, macular degeneration, retrolental fibroplasia and neovascular glaucoma.

One embodiment of the present invention provides a method of treatment of ophthalmologic disorders, diseases or conditions in which carbonic anhydrase is implicated or involved in metabolic pathways that influence the disorder, disease or condition comprising therapeutically effective amounts of Compound I, II, III, IV, V, VI or VII in combination with other glaucoma drugs whether or not the agents are administered orally, topically to the eye or other method of delivery, the glaucoma drugs including, but not limited to, acetazolamide; osmotic diuretics; pilocarpine; beta blockers.

Further, the present invention includes the treatment of ophthalmological diseases or disorders comprising the administration of therapeutically effective amounts of Compounds I, II, III, IV, V, VI or VII with one or more intraophthalmic or ocular pressure-reducing drugs including, without limitation latanoprost, travoprost, bimatoprost, or unoprostone.

Any drug having utility in a topical ophthalmic application can be used in co-

therapy, co-administration or co-formulation with Compound I, II, III, IV, V, VI or VII in methods of treatment of ophthalmological diseases or disorders in which carbonic anhydrase is implicated or involved in metabolic pathways that influence the diseases or conditions. Such drugs include without limitation demulcents; antibiotics, antivirals and other anti-infectives; steroids, NSAIDs and other anti-inflammatory agents; acetylcholine blocking agents; adrenergic agonists, beta-adrenergic blocking agents and other antiglaucoma agents; antihypertensives; antihistamines; anticataract agents; and topical and regional anesthetics. Illustrative specific drugs include acebutolol, aceclidine, acetylsalicylic acid (aspirin), N⁴ acetylsulfisoxazole, alclofenac, alprenolol, amfenac, amiloride, aminocaproic acid, *p*-aminoclonidine, aminozolamide, anisindione, apafant, atenolol, bacitracin, benoxaprofen, benoxinate, benzofenac, bepafant, betamethasone, betaxolol, bethanechol, brimonidine, bromfenac, bromhexine, bucloxic acid, bupivacaine, butibufen, carbachol, carprofen, cephalexin, chloramphenicol, chlordiazepoxide, chlorprocaine, chlorpropamide, chlortetracycline, cicloprofen, cinmetacin, ciprofloxacin, clidanac, clindamycin, clonidine, clonixin, clopirac, cocaine, cromolyn, cyclopentolate, cyproheptadine, demecarium, dexamethasone, dibucaine, diclofenac, diflusal, dipivefrin, dorzolamide, enoxacin, eperezolid, epinephrine, erythromycin, eserine, estradiol, ethacrynic acid, etidocaine, etodolac, fenbufen, fenclofenac, fenclorac, fenoprofen, fentiazac, flufenamic acid, flufenisal, flunoxaprofen, fluorocinolone, fluorometholone, flurbiprofen and esters thereof, fluticasone propionate, furaprofen, furobufen, furofenac, furosemide, gancyclovir, gentamycin, gramicidin, hexylcaine, homatropine, hydrocortisone, ibufenac, ibuprofen and esters thereof, idoxuridine, indomethacin, indoprofen, interferons, isobutylmethylxanthine, isofluorophate, isoproterenol, isoxepac, ketoprofen, ketorolac, labetolol, lactorolac, levo-bunolol,

lidocaine, linezolid, lonazolac, loteprednol, meclofenamate, medrysone, mefenamic acid, mepivacaine, metaproterenol, methanamine, methylprednisolone, metiazinic, metoprolol, metronidazole, minopafant, miroprofen, modipafant, nabumetome, nadolol, namoxyrate, naphazoline, naproxen and esters thereof, neomycin, nepafenac, nitroglycerin, norepinephrine, norfloxacin, nupafant, ofloxacin, olopatadine, oxaprozin, oxepinac, oxyphenbutazone, oxyprenolol, oxytetracycline, penicillins, perfloxacin, phenacetin, phenazopyridine, pheniramine, phenylbutazone, phenylephrine, phenylpropanolamine, phospholine, pilocarpine, pindolol, pirazolac, piroxicam, piroprofen, polymyxin, polymyxin B, prednisolone, prilocaine, probenecid, procaine, proparacaine, protizinic acid, rimexolone, salbutamol, scopolamine, sotalol, sulfacetamide, sulfanilic acid, sulindac, suprofen, tenoxicam, terbutaline, tetracaine, tetracycline, theophyllamine, timolol, tobramycin, tolmetin, triamcinolone, trimethoprim, trospectomycin, vancomycin, vidarabine, vitamin A, warfarin, zomepirac and pharmaceutically acceptable salts thereof.

The invention provides that Compound V (celecoxib) and Compound VII (valdecoxib) can be administered alone to a subject having a disease or condition in which carbonic anhydrase is a factor and in which inflammation is present.

In another embodiment of the present invention, carbonic anhydrase inhibitors, preferably, Compounds I, II, III, IV, V, VI VII, XI, XII or XIII are combined with antineoplastic drugs or agents, anticancer drugs or agents or antiangiogenic drugs or agents in methods of treatment and prevent of diseases in which carbonic anhydrase inhibitors combined with antineoplastic drugs or agents, anticancer drugs or agents or antiangiogenic or antineoplastic agents are effective.

The Compounds I, II, III, IV, V, VI VII, XI, XII or XIII are combined with antineoplastic agents which include antimetabolite agents, alkylating agents,


antibiotic-type agents, hormonal anticancer agents, immunological agents, interferon-type agents, and a category of miscellaneous antineoplastic agents to treat neoplastic diseases or conditions in which carbonic anhydrase also is implicated. These neoplastic diseases and conditions include, but are not limited to, renal cancer, leukemia, non-small cell lung cancer, ovarian cancer, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. Even more preferably the compounds I, II, III, IV, V, VI, VII, XI, XII or XIII are combined with pyrimidine analogs and, more preferably, the compounds are used in combinations with 5 fluorouracil (5-FU) and prodrugs of 5-FU such as 1-phthalidyl 5 fluorouracil (PH-FU) to enhance effectiveness of the I, II, III, IV, V, VI, VII, XI, XII or XIII.

As set out above, related compounds, for example compounds having the general structure of Formula 1, which include a sulfonamide group and inhibit carbonic anhydrase, may be used in the methods of the present invention and are intended to be included within the scope of the appended claims. Therefore, the foregoing description and examples are intended to be illustrative of the methods of the present invention and should not be construed in a limiting sense.

CLAIMS:

What is claimed is:

1. A method of treating or preventing a carbonic anhydrase associated disorder in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase inhibitor treating- or preventing- effective amount of a compound of Formula 1:



1.

wherein A is selected from the group consisting of partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

wherein R¹ is selected from the group consisting of heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R² is selected from the group consisting of amino and aminoalkylcarbonyl; and


wherein R³ is selected from the group consisting of a radical selected from H, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy,

alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, alkylthiocarbonyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl; and heterocyclalkylaminocarbonyldialkoxyaminoalkylcarbonylthionyl, or a pharmaceutically acceptable salt or prodrug thereof to treat or prevent the disorder.

2. The method of claim 1 wherein the compound is a cyclooxygenase inhibitor.

3. The method of claim 2 wherein in the cyclooxygenase inhibitors is a cyclooxygenase -2 inhibitor.





4. The method of claim 2 wherein in the cyclooxygenase inhibitors is a compound of the formula:



IV



or a pharmaceutically acceptable salt or prodrug thereof.

5. The method of claim 3 wherein the cyclooxygenase-2 inhibitor is a compound selected from the group consisting of




or pharmaceutically acceptable salt thereof or prodrug.

6. The method of claim 3 wherein the cyclooxygenase-2 inhibitor is a compound selected from the group of compounds consisting of the formulas:




or pharmaceutically acceptable salt or prodrug thereof.

7. The method of claim 6 wherein the prodrug of compound formula



VII

is compound formula



XIII.

8. The method of claim 1 wherein the disorder is selected from the group of disorders consisting of: edema associated with congestive heart failure, drug-induced edema, open-angle glaucoma, secondary glaucoma, acute angle closure glaucoma, epilepsy, acute mountain sickness, familial periodic paralysis, metabolic alkalosis, optic neuropathy, pseudomotor cerebri, cystoid macular edema and cystoid macular edema.


9. The method of claim 1 wherein the carbonic anhydrase associated disorder is a neoplastic disorder.

10. The method of claim 9 wherein the neoplastic disorder is selected from the group of neoplastic disorders consisting of: renal cancer, leukemia, lung cancer,


ovarian cancer, melanoma, colon cancer, cancer of the central nervous system, prostate cancer and breast cancer.

11. A method of treating or preventing a carbonic anhydrase associated disorder in a subject in need of such treatment or prevention comprising the administration to the subject a carbonic anhydrase associated disorder treating- or preventing-effective amount of a cyclooxygenase-2 inhibitor compound having a sulfonamide structure thereon, a pharmaceutically acceptable salt or prodrug thereof to treat or prevent the disorder.


12. The method of claim 11 wherein the cyclooxygenase-2 inhibitor compound having a sulfonamide structure thereon is selected from the group consisting of



I,




V,



VII,


and




VI;

or pharmaceutically acceptable salt or prodrug thereof.

13. The method of claim 11 wherein the cyclooxygenase-2 inhibitor compound having a sulfonamide structure thereon is selected from the group consisting of



XI,



and

XII;






or a pharmaceutically acceptable salt or prodrug thereof.

14. The method of claim 11 wherein the carbonic anhydrase associated disorder is a neoplastic disorder selected from the group of neoplastic disorders consisting of renal cancer, leukemia, lung cancer, ovarian cancer, melanoma, colon cancer, cancer of the central nervous system, prostate cancer and breast cancer.

15. The method of claim 11 wherein the carbonic anhydrase associated disorder is an ophthalmic disorder selected from the group of ophthalmic disorders

consisting of open angle glaucoma, acute angle closure glaucoma, optic neuropathy, and cystoid macular edema.


16. A method of treatment of a neoplastic disorder or disease comprising the administration of neoplastic disorder- or disease treatment- effective amount of a carbonic anhydrase inhibitor compound selected from the group of compounds of the formulas




or a pharmaceutically acceptable salt or prodrug thereof.

17. The method of claim 16 wherein the neoplastic disorder or disease is selected from the group of neoplastic disorders consisting of: renal cancer, leukemia, lung cancer, ovarian cancer, melanoma, colon cancer, cancer of the central nervous system, prostate cancer, and breast cancer.


18. A method for treating or preventing a neoplastic disease or disorder in a subject in need of such treatment or prevention, comprising administering to the subject an amount of an antineoplastic agent and an amount of a carbonic anhydrase inhibitor compound, said carbonic anhydrase inhibitor compound selected from the group of carbonic anhydrase inhibitor compounds consisting of the compounds of formula




I.;




II.;



III.;



IV.; and



VI.

or a pharmaceutically acceptable salt or prodrug thereof; and
wherein the amount of the antineoplastic agent and the amount of the carbonic anhydrase inhibitor compound together comprise a neoplastic disorder treating- or preventing-amount of the antineoplastic agent and the carbonic anhydrase inhibitor compound.

19. The method of claim 18 wherein said antineoplastic agent is selected from the group consisting of an antimetabolite agent, an alkylating agent, an antibiotic-type agent, a hormonal anticancer agent, an immunological agent, and an interferon-type agent.

20. The method of claim 18 wherein the antineoplastic agent is 1-phthalidyl 5-fluorouracil.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/013655 A3

(51) International Patent Classification⁷: **A61P 3/12**, 7/10,
21/00, 25/08, 27/02, 27/06, 35/00, 35/02, 43/00, A61K
31/635, 45/06, 31/18, 31/415, 31/42, 31/4188

(21) International Application Number: PCT/US02/25447

(22) International Filing Date: 9 August 2002 (09.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/311,561 10 August 2001 (10.08.2001) US

(71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Department, 800 N. Lindbergh Boulevard - 04E, St. Louis, MO 63167 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **O'NEAL, Janet, M.** [US/US]; 4046 Parker Avenue, St. Louis, MO 63116 (US).
MASFERRER, Jaime, L. [CL/US]; 812 Courtwood Lane, Ballwin, MO 63011 (US).

(74) Agent: **DOTY, Kathryn, J.**; Senniger, Powers, Leavitt & Roedel, 16th Floor, One Metropolitan Square, St. Louis, MO 63102 (US).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
14 August 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARBONIC ANHYDRASE INHIBITORS

(57) Abstract: Methods of treating or preventing carbonic anhydrase associated disorders or diseases in a subject in need of such treatment as prevention comprising the administration of cyclooxygenase -2 inhibitors, or structurally related compounds, having carbonic anhydrase inhibitory properties, as well as combinations of the cyclooxygenase -2 inhibitors, or structurally related compounds, with anti-inflammatory agents or drugs, antineoplastic agents or drugs or ophthalmic agents or drugs in methods of treatment and prevention of disorders or diseases.

WO 03/013655 A3

International Application No
PCT/US 02/25447

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inventor's Application No
PCT/US 02/25447

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 38986 A (GRANETO MATTHEW J ;BROWN DAVID L (US); SEARLE & CO (US); TALLEY JO) 23 October 1997 (1997-10-23) page 112, line 14 -page 113, line 7 page 114; table 1 ---	1-3,8,11
A	GRÜNEBERG, S. ET AL.,: "Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II." ANGEW. CHEM. INT. ED., vol. 40, no. 2, - 2001 pages 389-393, XP001126207 page 391; table 1 ---	1-8, 11-13
A	US 5 944 021 A (RODRIGUEZ VICTORIO C) 31 August 1999 (1999-08-31) claims 1-20 -----	1-8, 11-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/25447

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-8 and 11-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8, 11-13 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-8 (partially) and 11-13 (partially)

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of edema, including edema associated with congestive heart failure and drug-induced edema.

2. Claims: 1-8 (partially), 11-13 (partially) and 15.

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of ophthalmic disorders, including open-angle glaucoma, secondary glaucoma, acute angle closure glaucoma, optic neuropathy and cystoid macular edema.

3. Claims: 1-8 (partially) and 11-13 (partially).

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of epilepsy.

4. Claims: 1-8 (partially) and 11-13 (partially).

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of acute mountain sickness.

5. Claims: 1-8 (partially) and 11-13 (partially).

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of familial periodic paralysis.

6. Claims: 1-8 (partially) and 11-13 (partially).

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of metabolic alkalosis.

7. Claims: 1-8 (partially) and 11-13 (partially).

COX-2 inhibitors having a sulfonamide structure according to formula 1 for the manufacture of a medicament for the treatment of pseudomotor cerebri.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-7 (partially), 9-10, 11-13 (partially),
14 and 16-20.

COX-2 inhibitors having a sulfonamide structure according to
formula 1 for the manufacture of a medicament for the
treatment of neoplastic disorders.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-7 and 11-13 relate to the treatment of a disease which actually is not well defined.

The use of the definition "a carbonic anhydrase associated disorder" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is not fully possible to determine the diseases for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful complete search of the first invention impossible.

Present claims 1-3 and 8 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Furthermore, present claim 11 relates to a compound defined by reference to a desirable characteristic or property, namely "a cyclooxygenase-2 inhibitor compound having a sulfonamide structure thereon."

The claim cover all sulfonamides having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claim lacks so support, and the application lacks so disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, claim 11 also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to its pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole scope of the claim impossible.

In addition, present claims 1, 4-6 and 11-13 relate to a large number of possible compounds in terms of "prodrug". In fact, the claims contain so many options that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search over the whole scope of the claims impossible.

Consequently, the search of the first invention has been carried out for those parts of the application which do appear to be clear, concise, supported and disclosed, namely compounds according to formula 1 of claim 1 where A is a 1,2-diazole, 1,2-isoxazole or 1,3-oxazole, and in particular compounds I to VII and XI to XIII in relation to the treatment of edema, in particular drug-induced edema and edema associated with congestive heart failure with due regard to the general idea underlying the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inventor Application No

PCT/US 02/25447

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0128548	A	26-04-2001	AU 8026200 A	30-04-2001
			WO 0128548 A1	26-04-2001
			US 6323226 B1	27-11-2001

US 5760068	A	02-06-1998	US 5521207 A	28-05-1996
			US 5466823 A	14-11-1995
			US 6492411 B1	10-12-2002
			US 6156781 A	05-12-2000
			US 6413960 B1	02-07-2002
			AT 187965 T	15-01-2000
			AT 212985 T	15-02-2002
			AT 233245 T	15-03-2003
			AT 219937 T	15-07-2002
			AU 690609 B2	30-04-1998
			AU 1171495 A	19-06-1995
			CA 2177576 A1	08-06-1995
			CN 1141630 A ,B	29-01-1997
			CN 1280125 A	17-01-2001
			CN 1280126 A	17-01-2001
			CZ 9601503 A3	11-12-1996
			DE 69422306 D1	27-01-2000
			DE 69422306 T2	18-05-2000
			DE 69429836 D1	21-03-2002
			DE 69429836 T2	18-07-2002
			DE 69430930 D1	08-08-2002
			DE 69430930 T2	20-02-2003
			DE 69432193 D1	03-04-2003
			DK 731795 T3	15-05-2000
			DK 924201 T3	21-05-2002
			DK 923933 T3	21-10-2002
			EP 0731795 A1	18-09-1996
			EP 0924201 A1	23-06-1999
			EP 0922697 A1	16-06-1999
			EP 0923933 A1	23-06-1999
			ES 2141916 T3	01-04-2000
			ES 2172959 T3	01-10-2002
			ES 2180233 T3	01-02-2003
			FI 962249 A	29-05-1996
			GR 3032696 T3	30-06-2000
			HK 1013649 A1	07-07-2000
			HU 74180 A2	28-11-1996
			JP 2000109466 A	18-04-2000
			JP 3025017 B2	27-03-2000
			JP 9506350 T	24-06-1997
			KR 229343 B1	01-11-1999
			KR 263817 B1	16-08-2000
			KR 261669 B1	15-07-2000
			LU 90698 A9	13-02-2001
			NO 962184 A	29-05-1996
			NZ 276885 A	30-08-1999
			PL 314695 A1	16-09-1996
			PT 731795 T	31-05-2000
			PT 924201 T	28-06-2002
			PT 923933 T	31-10-2002

EP 0826676	A	04-03-1998	JP 3181190 B2	03-07-2001
			JP 8325249 A	10-12-1996
			EP 0826676 A1	04-03-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/25447

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0826676	A	US 5945539 A	31-08-1999
		AT 180253 T	15-06-1999
		AU 695045 B2	06-08-1998
		AU 4189796 A	10-07-1996
		BR 9506815 A	09-09-1997
		CA 2183645 A1	27-06-1996
		CA 2208316 A1	27-06-1996
		CA 2341921 A1	27-06-1996
		CN 1146204 A	26-03-1997
		CZ 9602749 A3	11-12-1996
		DE 69509753 D1	24-06-1999
		DE 69509753 T2	02-12-1999
		DK 745596 T3	08-11-1999
		EP 0745596 A1	04-12-1996
		ES 2132751 T3	16-08-1999
		FI 963238 A	17-10-1996
		GR 3030643 T3	29-10-1999
		HU 76541 A2	29-09-1997
		WO 9619462 A1	27-06-1996
		WO 9619463 A1	27-06-1996
		JP 2636819 B2	30-07-1997
		JP 9052882 A	25-02-1997
		KR 201581 B1	15-06-1999
		NO 963450 A	04-10-1996
		NZ 297105 A	22-09-1997
		SK 117596 A3	07-05-1997
		TW 403742 B	01-09-2000
		US 6002014 A	14-12-1999
		US 6362209 B1	26-03-2002
		US 5994381 A	30-11-1999
		US 2002143040 A1	03-10-2002
		US 2002107270 A1	08-08-2002
		US 2002107271 A1	08-08-2002
		US 2002198244 A1	26-12-2002
		US 2002115701 A1	22-08-2002
		US 2002198245 A1	26-12-2002

WO 9738986	A	23-10-1997	
		AP 1009 A	21-09-2001
		AT 233743 T	15-03-2003
		AU 734275 B2	07-06-2001
		AU 2722797 A	07-11-1997
		BG 102916 A	31-08-1999
		BR 1100403 A3	25-07-2000
		BR 9708574 A	03-08-1999
		CA 2249009 A1	23-10-1997
		CN 1216043 A ,B	05-05-1999
		CZ 9802710 A3	13-01-1999
		DE 69719496 D1	10-04-2003
		EE 9800351 A	15-04-1999
		EP 1288206 A1	05-03-2003
		EP 0892791 A1	27-01-1999
		HU 9901807 A2	28-09-1999
		JP 3382624 B2	04-03-2003
		JP 2000509029 T	18-07-2000
		KR 2000005395 A	25-01-2000
		LT 98142 A ,B	26-07-1999
		LV 12239 A	20-03-1999
		LV 12239 B	20-08-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 02/25447

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9738986	A	NO 984727 A	14-12-1998
		NZ 331542 A	29-07-1999
		PL 329276 A1	15-03-1999
		SI 9720035 A	30-06-1999
		SK 124298 A3	13-04-1999
		TR 9802049 T2	18-01-1999
		US 5932598 A	03-08-1999
		WO 9738986 A1	23-10-1997
		US 6436967 B1	20-08-2002
		ZA 9703146 A	14-04-1998

US 5944021	A	31-08-1999	
		US 5755237 A	26-05-1998
		AU 2763299 A	30-08-1999
		CA 2320934 A1	19-08-1999
		EP 1059889 A1	20-12-2000
		JP 2002502863 T	29-01-2002
		WO 9940867 A1	19-08-1999
		AU 6147296 A	30-12-1996
		CA 2196873 A1	19-12-1996
		EP 0776182 A1	04-06-1997
		JP 11500739 T	19-01-1999
		WO 9639978 A1	19-12-1996